Singapore markets close in 1 hour 40 minutes

Lyra Therapeutics, Inc. (LYRA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.0300-0.6000 (-12.96%)
At close: 04:00PM EDT
4.2200 +0.19 (+4.71%)
After hours: 07:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.6300
Open4.6600
Bid4.0100 x 100
Ask4.0500 x 500
Day's range3.9300 - 4.7099
52-week range2.3600 - 6.7900
Volume2,439,825
Avg. volume373,395
Market cap245.689M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

    -- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May --WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2024 and provided a corporate update. “With results

  • GlobeNewswire

    Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Thera

  • GlobeNewswire

    Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

    -- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate